Skip to main content
. Author manuscript; available in PMC: 2021 May 19.
Published in final edited form as: Circulation. 2020 Mar 29;141(20):1600–1607. doi: 10.1161/CIRCULATIONAHA.120.046397

Figure 4: Benefit of Evolocumab for Reducing VTE by Genetic Risk Category.

Figure 4:

Patients in the top one third of genetic risk had a 55% relative risk reduction (HR 0.45 [0.21–0.95], p=0.035) and 0.7% absolute risk reduction (95% CI 0.2,1.3). The VTE reduction was significantly greater in patients with high genetic risk compared to not-high genetic risk (Pinteraction= 0.04; Pheterogeneity= 0.009).